Boceprevir and Pravigard Pac

In the database of official manuals used in the service creation an interaction registered by statistical results of studies was found, which can either lead to negative consequences for the patient health or strengthen a mutual positive effect. A doctor should be consulted to address the issue of joint drug administration.

Boceprevir may increase the blood levels and effects of pravastatin. This can increase the risk of side effects such as liver damage and a rare but serious condition called rhabdomyolysis that involves the breakdown of skeletal muscle tissue. In some cases, rhabdomyolysis can cause kidney damage and even death. You may need a dose adjustment or more frequent monitoring by your doctor to safely use both medications, or your doctor may prescribe alternative medications that do not interact. Let your doctor know immediately if you have unexplained muscle pain, tenderness, or weakness during treatment with pravastatin or similar medications, especially if these symptoms are accompanied by fever or dark colored urine. You should also seek immediate medical attention if you develop fever, chills, joint pain or swelling, unusual bleeding or bruising, skin rash, itching, loss of appetite, fatigue, nausea, vomiting, dark colored urine, light colored stools, and/or yellowing of the skin or eyes, as these may be signs and symptoms of liver damage. It is important to tell your doctor about all other medications you use, including vitamins and herbs. Do not stop using any medications without first talking to your doctor.

MONITOR: Coadministration with boceprevir may increase the plasma concentrations of pravastatin. The mechanism of interaction has not been described. In study subjects, administration of a single 40 mg dose of pravastatin in combination with boceprevir 800 mg three times daily for 6 days resulted in a 49% increase in mean pravastatin peak plasma concentration (Cmax) and 63% increase in systemic exposure (AUC) compared to administration of pravastatin alone. No significant effect on the pharmacokinetics of boceprevir was observed. Clinically, high levels of HMG-CoA reductase inhibitory activity in plasma may be associated with an increased risk of musculoskeletal toxicity. Myopathy manifested as muscle pain and/or weakness associated with grossly elevated creatine kinase exceeding ten times the upper limit of normal has been reported occasionally. Rhabdomyolysis has also occurred rarely, which may be accompanied by acute renal failure secondary to myoglobinuria and may result in death.

MANAGEMENT: Treatment with pravastatin can be initiated at the normally recommended dosage when coadministered with boceprevir. However, close monitoring of clinical response and careful titration of pravastatin dosage are warranted. Alternatively, other HMG-CoA reductase inhibitors that have not been reported to interact with boceprevir may be considered, such as fluvastatin, pitavastatin, and rosuvastatin. All patients treated with HMG-CoA reductase inhibitors should be advised to promptly report any unexplained muscle pain, tenderness, or weakness, particularly if accompanied by malaise or fever. Therapy should be discontinued if creatine kinase is markedly elevated in the absence of strenuous exercise or if myopathy is otherwise suspected or diagnosed.

Boceprevir

Generic Name: boceprevir

Brand name: Victrelis

Synonyms: Boceprevir (Oral)

What is Boceprevir?

Pravigard Pac

Generic Name: aspirin / pravastatin

Brand name: Pravigard Pac

Synonyms: Pravigard PAC

What is Pravigard Pac?